Brian Rosin Acquires 5,100 Shares of Prenetics Global (NASDAQ:PRE) Stock

Prenetics Global Limited (NASDAQ:PRE) CFO Brian Rosin bought 5,100 shares of Prenetics Global stock in a transaction dated Tuesday, August 25th. The stock was acquired at an average cost of $22.80 per share, for a total transaction of $116,280.00. Following the completion of the acquisition, the chief financial officer directly owned 23,100 shares in the company, valued at $526,680. This represents a 28.33% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Prenetics Global Price Performance

PRE stock opened at $26.25 on Friday. The business has a fifty day moving average price of $19.36 and a 200 day moving average price of $19.03. Prenetics Global Limited has a fifty-two week low of $7.27 and a fifty-two week high of $26.50. The stock has a market capitalization of $442.94 million, a price-to-earnings ratio of -6.31 and a beta of 0.26.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. The company had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.85 million. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%. On average, equities analysts expect that Prenetics Global Limited will post -1.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PRE. Wall Street Zen upgraded shares of Prenetics Global from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Benchmark increased their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, B. Riley Financial started coverage on shares of Prenetics Global in a report on Thursday. They issued a “buy” rating and a $37.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Prenetics Global has an average rating of “Moderate Buy” and a consensus target price of $34.80.

Key Headlines Impacting Prenetics Global

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: IM8 CEO Danny Yeung and CFO Brian Rosin purchased approximately $1.0 million of Prenetics shares in open-market transactions between August 20 and August 25, following the release of second-quarter results. Company leadership’s cumulative personal investment since November 2025 has reached roughly $3.75 million, providing a strong insider-confidence signal. Prenetics IM8 CEO and CFO Purchase $1.0 Million of Shares
• Positive Sentiment: B. Riley Financial initiated coverage of PRE with a “buy” rating and a $37 price target, implying approximately 41% upside from the referenced share price. The new coverage adds to a generally favorable analyst view; four analysts rate the stock Buy and one rates it Sell, with a consensus target of $34.25. B. Riley initiates coverage of Prenetics Global
• Positive Sentiment: CFO Brian Rosin separately bought 18,000 shares at an average $21.19 and another 5,100 shares at $22.80, investing about $497,700 in total and increasing his ownership substantially. These purchases were disclosed in SEC filings and reinforce the broader insider-buying catalyst. Insider Buying: Prenetics Global CFO Purchases Shares
• Neutral Sentiment: Prenetics reported second-quarter EPS of negative $0.53, better than the expected negative $0.84, but revenue of $46.49 million missed the $49.85 million consensus estimate. The company remains loss-making, with a negative net margin and analysts forecasting a full-year loss.
• Negative Sentiment: The stock is trading near its 52-week high after a sharp advance, which may increase valuation and profit-taking risks if Prenetics does not accelerate revenue growth or improve profitability.

Hedge Funds Weigh In On Prenetics Global

Several large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in Prenetics Global in the third quarter worth about $65,000. UBS Group AG raised its holdings in Prenetics Global by 581.9% during the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock worth $619,000 after purchasing an additional 39,733 shares during the last quarter. Kingsview Wealth Management LLC acquired a new position in Prenetics Global during the 4th quarter valued at about $172,000. Goldman Sachs Group Inc. acquired a new position in Prenetics Global during the 4th quarter valued at about $665,000. Finally, T3 Companies LLC acquired a new position in Prenetics Global during the 4th quarter valued at about $170,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.